Solid Biosciences (SLDB) investor relations material

Executive summary

• Advanced gene therapy candidates for rare neuromuscular and cardiac diseases, including SGT-003 (Duchenne muscular dystrophy), SGT-212 (Friedreich's ataxia), SGT-501 (CPVT), and SGT-601 (TNNT2 DCM), with multiple clinical and preclinical programs ongoing.

• SGT-003 and SGT-212 received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA; SGT-003 also has EU Orphan Drug and UK Innovation Passport status.

• SGT-003 Phase 1/2 trial dosed 53 participants with favorable safety; Phase 3 trial underway with global site expansion planned.

• SGT-212 Phase 1b trial ongoing with two participants dosed and initial data expected in Q1 2027.

• SGT-501 Phase 1b trial site activation and participant screening commenced; first dosing expected in H2 2026.

Financial highlights

• Net loss for Q2 2026 was $54.8 million, up from $39.5 million in Q2 2025; net loss for the six months ended June 30, 2026 was $111.5 million, up from $78.8 million year-over-year.

• Research and development expenses rose 36.6% year-over-year to $44.3 million for Q2 2026, mainly due to increased SGT-003 and SGT-212 costs.

• General and administrative expenses increased 41.4% to $13.1 million for Q2 2026, mainly due to higher personnel and business development costs.

• Cash, cash equivalents, and available-for-sale securities totaled $377.7 million as of June 30, 2026, up from $187.9 million at December 31, 2025, with no outstanding debt.

• Financing activities in H1 2026 provided $287.5 million, primarily from a $226.3 million private placement and $60.8 million from at-the-market offerings.

Outlook and guidance

• Cash runway is expected to fund operations into mid-2028, supporting late-stage development and early pipeline, but additional capital will be needed beyond that period.

• FDA meeting for SGT-003 data package and accelerated approval pathway planned for late Q4 2026.

• Initial data from the FALCON trial (SGT-212) and ARTEMIS trial (SGT-501) expected in 2027, with ongoing regulatory and clinical milestones planned.

• SGT-501 first participant dosing expected in H2 2026, with safety data in H1 2027.